EV-miRNAs as biomarkers of breast cancer recurrence
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA992498 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:To evaluate the miRNAs expression related to breast cancer recurrence
2024-08-14 | GSE236845 | GEO
Project description: Not available
| S-EPMC11298852 | biostudies-literature
Project description:Introduction: MicroRNAs (miRNAs) are small, non-coding RNA molecules involved in post-transcriptional gene regulation and have recently been shown to play a role in cancer metastasis. In solid tumors, especially breast cancer, alterations in miRNA expression contribute to cancer pathogenesis, including metastasis. Considering the emerging role of miRNAs in metastasis, the identification of predictive markers is necessary to further understanding of stage-specific breast cancer development. This is a retrospective analysis that aimed to identify molecular biomarkers related to distant breast cancer metastasis development.<br><br>Methods: A retrospective case cohort study was performed in 64 breast cancer patients treated during the period from 1998-2001. The case group (n=29) consisted of patients with a poor prognosis who presented with breast cancer recurrence or metastasis during follow up. The control group (n=35) consisted of a random sample of patients with a good prognosis who did not develop breast cancer recurrence or metastasis. These patient groups were stratified according to TNM clinical stage (CS) I, II and III, and the main clinical features of the patients were homogeneous. miRNA profiling was performed using formalin-fixed, paraffin-embedded tumors. Biomarkers related to metastatic potential were identified independent of clinical stage, and a cutoff point was selected based on the optimal sensitivity and specificity (ROC curve). Finally, a hazard risk analysis of these biomarkers was performed to evaluate their relation to metastatic potential. <br><br>Results: miRNA expression profiling identified several miRNAs that were either specific and shared across all clinical stages (p?0.05). Among these, we identified miRNAs previously associated with cell motility (let-7 family), cell proliferation and invasion (hsa-miR-16 and has-miR-205) and distant metastasis (hsa-miR-21). In addition, hsa-miR-494 and hsa-miR-21 were up-regulated in metastatic cases of CSI and II. Furthermore, the combination of the 3 miRNAs identified for CSII (hsa-miR-494, hsa-miR-183 and hsa-miR-21) was significant and were a more effective risk marker compared to the single miRNAs. <br><br>Conclusions: Women with metastatic breast cancer, especially CSII, presented up-regulated levels of miR-183, miR-494 and miR-21, which were associated with a poor prognosis. These miRNAs therefore represent new risk biomarkers of breast cancer metastasis and may be useful for future targeted therapies.
2013-08-07 | E-MEXP-3947 | biostudies-arrayexpress
Project description:Expression of miRNAs in ovarian cancer recurrence
| PRJNA558993 | ENA
Project description:This SuperSeries is composed of the following subset Series: GSE26022: [Gene Expression Training Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy GSE26242: [Gene Expression Validation Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy GSE26245: [miRNA Training Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy GSE26247: [miRNA Validation Set] Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy Refer to individual Series
2011-06-01 | E-GEOD-26367 | biostudies-arrayexpress
Project description:Circulating microRNAs (miRNAs) may be able to serve as prognostic biomarkers. However, identifying the accurate screening method/s for miRNA detection/quantification from serum is crucial for any further downstream analysis. Here, we compared two high-throughput methods, small RNA sequencing (sRNA-seq) and TaqMan Low-Density Array (TLDA), to quantify miRNAs at baseline (time of primary surgery) in the serum from ER+ BC patients for whom the long-term clinical follow-up information (10 years) and subsequent metastasis status are known. For this study, 48 serum samples were selected based on the outcome of breast cancer patients, and therefore sub-divided in: patients with no recurrence within a 10-years period (Cohort 1, n=16), patients with early recurrence within 5 years (Cohort 2, <5 Years, n=16), or patients with late recurrence after 5 years up to 10 years (Cohort 3, >5 Years, n=16). For each serum sample, the miRNome analysis was performed by Next Generation Sequencing (NGS) using 20 µl of the 45 µl total RNA extracted from 200 µl serum by the miRCURY Biofluids RNA Isolation Kit. The NGS libraries were constructed and sequenced at the ProfileXpert platform (www.profilexpert.fr). The data was quality checked by assigning Q-scores after the intensity correction and base calling. The raw data were treated with the NCS 2.0.2 and RTA 2.4.11 software’s to generate the Base Calling File. The Bcl2factq v2.17.1.14 was used to demultiplexing using 1 mismatch.
2025-01-01 | E-MTAB-10555 | biostudies-arrayexpress
Project description:Recurrence is the major cause of treatment failure in patients with ovarian cancer. The purpose of this study is to identify novel miRNAs contributing to ovarian cancer recurrence.
2019-08-15 | GSE135469 | GEO
Project description:Plasma miRNAs as biomarkers of epilepsy
| PRJNA1009812 | ENA
Project description:Molecular Determinants of Post-Mastectomy Breast Cancer Recurrence
2018-09-20 | PRJEB28702 | EVA
Project description:Background: Maternal pre-pregnancy BMI is a critical factor influencing the composition of breast milk. Breast milk has abundant extracellular vesicles (EVs) containing various biological molecules (cargo), including miRNAs. EVs are not degraded in the gastrointestinal system and circulation; thus, breast milk EVs (bEVs) interact with other organs in breastfed infants and modify the gene expression of recipient cells using miRNAs. In maternal obesity, miRNAs in bEVs are deregulated, which might be associated with adverse health outcomes in infants. In this study, we examined 798 miRNAs to determine which miRNAs are altered in the bEVs of obese mothers and their potential impact on breastfed infants. Methods: We recruited healthy nursing mothers who were either obese (BMI≥30) or lean (BMI<25) based on their pre-pregnancy BMI, and delivered a singleton baby in the prior six months. EVs were isolated from breast milk with ultracentrifugation. bEV characteristics were examined by flow cytometry and fluorescence imaging of EV markers. A total of 798 miRNAs were screened using a NanoString human miRNA panel to find deregulated miRNAs in bEVs of obese mothers compared to lean mothers. Results: We included 65 nursing mothers: 47 lean and 18 obese mothers based on pre-pregnancy BMI. After bEV isolation, we confirmed the expression of general EV markers. Out of 37 EV markers, CD326 was the most highly expressed marker in bEVs. From miRNA analysis using NanoString, we found that the most abundant miRNAs include miR-30b-5p, miR-494-3p, and let-7 families, and the list of top 10 miRNAs was not different between lean and obese mothers. Target genes of the top 10 miRNAs were associated with the EGFR, ErbB, and FoxO signaling pathway. Nineteen miRNAs were deregulated in bEVs of obese mothers (adjusted p < 0.05 cut-off), including miR-575, miR-548g-3p, miR-582-3p, and miR-652-5p. The target genes of these miRNAs are associated with lipid metabolism, inflammatory diseases, and nervous/cardiovascular system development. Conclusion: In this study, we demonstrated altered miRNAs in bEVs of obese mothers and identified the pathways of their potential target genes. Our findings will provide insight for future studies investigating the role of bEVs in breastfed infants.
2022-09-09 | GSE212951 | GEO